KBI Biopharma's PUREplatform is doing more with microbes
KBI Biopharma unveils its new microbial cell line development platform, the KBI PUREplatform. The system is set to improve the efficiency of microbial expression systems for biopharmaceutical production, whilst also addressing a variety of industry challenges.
Key information:
- KBI Biopharma is set to launch its new microbial cell line development platform, PUREplatform.
- The platform aims to solve industry challenges including capacity constraints, low titers, and poor product quality.
- KBI’s latest release combines its high-producing E. coli cell line, PUREcoli, with PUREplasmids and PUREmedia, with each protein expression tailored to each individual customer’s requirements.
The contract development and manufacturing organisation’s latest launch is set to address industry challenges including capacity constraints, low titers, and poor product quality. Set to be used for commercial use, the KBI PUREplatform combines KBI’s PUREcoli (its high-producing E. coli cell line) with PUREplasmids and PUREmedia, which will be available in 8, 24, 48, and 96 screen packages. And each protein expression is individually tailored to the customer’s requirements, with more strains and screening packages coming in the future.
“With the introduction of the KBI PUREplatform, we're poised to extend the boundaries of expression system and process synergy, underscoring KBI’s commitment to innovation and customer-centric solutions across all business segments,” said Sigma Mostafa, KBI Biopharma’s Chief Scientific Officer. “We always strive to stay a step ahead with significant production advancements. With this platform, we’re redefining the microbial expression landscape and raising the floor of efficiencies to create new market opportunities for scalable expression systems.”
PUREplatform boasts efficiency, predictive development, and scalable high throughput workflows which quickly feed upstream process development and late-stage manufacturing. KBI’s latest release, with PUREcoli, outperforms common K-12 or B strain E. coli, by growing 50% faster, which goes on to reduce production time. PUREcoli has 100 fewer virulence or immunogenicity-related genes, which eliminates the need for antibiotics in plasmid maintenance. Overall making PUREcoli safer and more efficient.
“The results our development team is seeing with PUREplatform are paving the way for our partners to realise microbial drug substance at a fraction of the scales previously needed, and we hope to see this translate into more efficient cost of goods for at-scale manufacturing,” said J.D. Mowery, Chief Executive Officer of KBI Biopharma.